Scientists report that psilocybin microdoses may reverse obesity, fatty liver, and diabetes through cellular metabolic effects

Psilocybin microdosing is presented as a potential metabolic intervention for obesity, fatty liver disease, and diabetes, with emphasis on effects observed at the cellular level. The central claim is that very low doses may influence pathways tied to fat storage, liver function, and glucose regulation rather than acting only through changes in mood or perception. The focus appears to be on emerging scientific findings that connect psilocybin to metabolic repair mechanisms. Those findings suggest possible benefits for conditions linked to insulin resistance and chronic inflammation, and they frame psychedelic research beyond mental health into broader physiological medicine. If those results hold up in stronger animal and human studies, psilocybin could become relevant to treatment strategies for major metabolic disorders. The significance lies in extending psychedelic science into obesity and liver disease research while keeping attention on dose, mechanism, and clinical validation.